This page explains the science of CAR-T cell therapy, including its mechanism of action and the structure of 4-1BB CAR-T cells, as well as efficacy, safety, and patient identification.
This page explains the manufacturing process of CAR-T cell therapy, including details such as leukapheresis, cryopreservation, and outpatient administration.
This page details the current landscape of treatment options for patients with haematologic malignancies, outlining key details about CAR-T cell therapy and standards of care such as stem cell transplant and cycling chemotherapy.
This page outlines the Novartis CAR-T legacy, explaining the history of CAR-T cell therapy and future areas for exploration.
This site is intended for a global audience.